{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T16:48:19Z","timestamp":1793119699227,"version":"4.5.0"},"reference-count":59,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T00:00:00Z","timestamp":1750204800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Optic neuritis (ON) is an inflammatory condition of the optic nerve that can lead to significant visual impairment. It is often associated with multiple sclerosis (MS) but can also occur in other demyelinating diseases, such as neuromyelitis optica spectrum disorder (NMOSD) and myelin oligodendrocyte glycoprotein antibody disease (MOGAD). Understanding the current therapeutic approaches and emerging treatment strategies is critical for optimizing patient outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This review provides a focused overview of current therapies for demyelinating optic neuritis associated with MS, NMOSD, and MOGAD. Less common autoimmune optic neuropathies, non-autoimmune causes (e.g., infections) and pediatric optic neuritis are not covered.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A review of the literature was conducted, including clinical trials, observational studies, and expert recommendations on the treatment and management of demyelinating ON. The efficacy, safety, and limitations of various therapeutic modalities were assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>High-dose intravenous corticosteroids remain the mainstay of acute demyelinating ON treatment, accelerating visual recovery but not altering long-term visual outcomes. Immunomodulatory therapies, such as disease-modifying treatments for MS, play a crucial role in preventing recurrent episodes in demyelinating diseases. Emerging therapies, including re-myelination agents, neuroprotective strategies, and novel immunotherapies, show promise in improving visual prognosis and reducing long-term disability.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>While corticosteroids remain the primary treatment for acute demyelinating ON, ongoing research into neuroprotective and re-myelinating therapies offers hope for better visual recovery and long-term management. Future studies should focus on optimizing treatment strategies and exploring novel therapeutics to enhance patient outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fneur.2025.1605075","type":"journal-article","created":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T03:22:58Z","timestamp":1750216978000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":14,"title":["Optic neuritis: a comprehensive review of current therapies and emerging treatment strategies"],"prefix":"10.3389","volume":"16","author":[{"given":"Pareena","family":"Chaitanuwong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather E.","family":"Moss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,6,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/S1474-4422(13)70259-X","article-title":"Optic neuritis","volume":"13","author":"Toosy","year":"2014","journal-title":"Lancet Neurol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1001\/archopht.126.7.994","article-title":"Treatment of acute optic neuritis: a summary of findings from the optic neuritis treatment trial","volume":"126","author":"Beck","year":"2008","journal-title":"Arch Ophthalmol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1001\/archopht.1988.01060140207023","article-title":"The optic neuritis treatment trial","volume":"106","author":"Beck","year":"1988","journal-title":"Arch Ophthalmol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol"},{"key":"B5","volume-title":"Revisions of the McDonald Criteria. Scientific Session 1: New diagnostic Criteria.","year":"2024"},{"key":"B6","doi-asserted-by":"publisher","first-page":"12952","DOI":"10.1073\/pnas.1912839117","article-title":"Inflammation-related plasma and CSF biomarkers for multiple sclerosis","volume":"117","author":"Huang","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B7","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1080\/08820538.2020.1866027","article-title":"MRI characteristics of NMO, MOG and MS related optic neuritis","volume":"35","author":"Winter","year":"2020","journal-title":"Semin Ophthalmol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"3128","DOI":"10.1093\/brain\/awx276","article-title":"Clinical presentation and prognosis in MOG-antibody disease: a UK study","volume":"140","author":"Jurynczyk","year":"2017","journal-title":"Brain"},{"key":"B9","doi-asserted-by":"publisher","first-page":"e1858","DOI":"10.1212\/WNL.0000000000005560","article-title":"Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: the MOGADOR study","volume":"90","author":"Cobo-Calvo","year":"2018","journal-title":"Neurology"},{"key":"B10","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"key":"B11","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/S1474-4422(22)00431-8","article-title":"Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: international MOGAD panel proposed criteria","volume":"22","author":"Banwell","year":"2023","journal-title":"Lancet Neurol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"Cd006921","DOI":"10.1002\/14651858.CD006921.pub3","article-title":"Oral versus intravenous steroids for treatment of relapses in multiple sclerosis","volume":"12","author":"Burton","year":"2012","journal-title":"Cochrane Database Syst Rev."},{"key":"B13","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1136\/ejhpharm-2018-001499","article-title":"High-dose oral methylprednisolone for the treatment of multiple sclerosis relapses: cost-minimisation analysis and patient's satisfaction","volume":"26","author":"Horta-Hern\u00e1ndez","year":"2019","journal-title":"Eur J Hosp Pharm."},{"key":"B14","doi-asserted-by":"publisher","first-page":"e504","DOI":"10.1212\/NXI.0000000000000504","article-title":"Apheresis therapies for NMOSD attacks: a retrospective study of 207 therapeutic interventions","volume":"5","author":"Kleiter","year":"2018","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B15","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1136\/jnnp-2017-316286","article-title":"Short delay to initiate plasma exchange is the strongest predictor of outcome in severe attacks of NMO spectrum disorders","volume":"89","author":"Bonnan","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B16","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1016\/S1474-4422(21)00218-0","article-title":"Myelin-oligodendrocyte glycoprotein antibody-associated disease","volume":"20","author":"Marignier","year":"2021","journal-title":"Lancet Neurol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1136\/jnnp-2017-316880","article-title":"Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination","volume":"89","author":"Ramanathan","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B18","doi-asserted-by":"publisher","first-page":"e572","DOI":"10.1212\/NXI.0000000000000572","article-title":"Does time equal vision in the acute treatment of a cohort of AQP4 and MOG optic neuritis?","volume":"6","author":"Stiebel-Kalish","year":"2019","journal-title":"Neurology Neuroimmunol Neuroinflamm."},{"key":"B19","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1002\/1531-8249(199912)46:6<878::aid-ana10>3.0.co;2-q","article-title":"A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease","volume":"46","author":"Weinshenker","year":"1999","journal-title":"Ann Neurol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1212\/01.WNL.0000152873.82631.B3","article-title":"A double-blind, randomized trial of IV immunoglobulin treatment in acute optic neuritis","volume":"64","author":"Roed","year":"2005","journal-title":"Neurology"},{"key":"B21","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1177\/1352458511415452","article-title":"Simvastatin improves final visual outcome in acute optic neuritis: a randomized study","volume":"18","author":"Tsakiri","year":"2012","journal-title":"Mult Scler J"},{"key":"B22","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1002\/ana.23573","article-title":"A randomized, double-blind, phase 2 study of erythropoietin in optic neuritis","volume":"72","author":"S\u00fchs","year":"2012","journal-title":"Ann Neurol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/S1474-4422(16)00004-1","article-title":"Phenytoin for neuroprotection in patients with acute optic neuritis: a randomised, placebo-controlled, phase 2 trial","volume":"15","author":"Raftopoulos","year":"2016","journal-title":"Lancet Neurol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/S1474-4422(16)30377-5","article-title":"Safety and efficacy of opicinumab in acute optic neuritis (RENEW): a randomised, placebo-controlled, phase 2 trial","volume":"16","author":"Cadavid","year":"2017","journal-title":"Lancet Neurol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1177\/1352458517742979","article-title":"Amiloride does not protect retinal nerve fibre layer thickness in optic neuritis in a phase 2 randomised controlled trial","volume":"25","author":"McKee","year":"2019","journal-title":"Mult Scler J"},{"key":"B26","doi-asserted-by":"publisher","first-page":"2055217319850193","DOI":"10.1177\/2055217319850193","article-title":"Oral lipoic acid as a treatment for acute optic neuritis: a blinded, placebo controlled randomized trial","volume":"5","author":"Falardeau","year":"2019","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12883-020-01645-z","article-title":"Fingolimod after a first unilateral episode of acute optic neuritis (MOVING) \u2013 preliminary results from a randomized, rater-blind, active-controlled, phase 2 trial","volume":"20","author":"Albert","year":"2020","journal-title":"BMC Neurol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1001\/jama.2020.26858","article-title":"Diagnosis and treatment of multiple sclerosis: a review","volume":"325","author":"McGinley","year":"2021","journal-title":"JAMA"},{"key":"B29","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.mayocp.2013.11.002","article-title":"Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies","volume":"89","author":"Wingerchuk","year":"2014","journal-title":"Mayo Clinic Proc."},{"key":"B30","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1097\/WCO.0b013e3283533a3f","article-title":"Neuromyelitis optica: not a multiple sclerosis variant","volume":"25","author":"Barnett","year":"2012","journal-title":"Curr Opin Neurol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1212\/WNL.0b013e3181f8832e","article-title":"IFN\u03b2-1b may severely exacerbate Japanese optic-spinal MS in neuromyelitis optica spectrum","volume":"75","author":"Shimizu","year":"2010","journal-title":"Neurology."},{"key":"B32","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s00415-015-7991-1","article-title":"Efficacy of glatiramer acetate in neuromyelitis optica spectrum disorder: a multicenter retrospective study","author":"Ayzenberg","year":"2016","journal-title":"J Neurol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"e66","DOI":"10.1212\/NXI.0000000000000066","article-title":"Unmasking and provoking severe disease activity in a patient with NMO spectrum disorder","volume":"2","author":"Kornberg","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B34","doi-asserted-by":"publisher","first-page":"e208","DOI":"10.1212\/NXI.0000000000000208","article-title":"Failure of alemtuzumab as a rescue in a NMOSD patient treated with rituximab","volume":"3","author":"Kowarik","year":"2016","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B35","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1097\/WNF.0000000000000430","article-title":"Severe relapses of neuromyelitis optica spectrum disorder during treatment with dimethyl fumarate","volume":"44","author":"Javadian","year":"2021","journal-title":"Clin Neuropharmacol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.jneuroim.2019.04.007","article-title":"Efficacy and tolerability of mitoxantrone for neuromyelitis optica spectrum disorder: a systematic review","volume":"332","author":"Enriquez","year":"2019","journal-title":"J Neuroimmunol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"P2.160","DOI":"10.1212\/WNL.86.16_supplement.P2.160","article-title":"Long-term effect of cyclosporine A in the prophylaxis of neuromyelitis optica spectrum disorders (P2.160)","volume":"86","author":"Kageyama","year":"2016","journal-title":"Neurology"},{"key":"B38","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1056\/NEJMoa1900866","article-title":"Eculizumab in aquaporin-4\u2013positive neuromyelitis optica spectrum disorder","volume":"381","author":"Pittock","year":"2019","journal-title":"N Engl J Med"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1016\/S0140-6736(19)31817-3","article-title":"Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2\/3 trial","volume":"394","author":"Cree","year":"2019","journal-title":"Lancet"},{"key":"B40","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/S1474-4422(20)30078-8","article-title":"Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial","volume":"19","author":"Traboulsee","year":"2020","journal-title":"Lancet Neurol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1056\/NEJMoa1901747","article-title":"Trial of satralizumab in neuromyelitis optica spectrum disorder","volume":"381","author":"Yamamura","year":"2019","journal-title":"N Engl J Med"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1002\/ana.26626","article-title":"Ravulizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder","volume":"93","author":"Pittock","year":"2023","journal-title":"Ann Neurol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1038\/s41433-020-01334-8","article-title":"Neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein associated disorder-optic neuritis: a comprehensive review of diagnosis and treatment","volume":"35","author":"Gospe","year":"2021","journal-title":"Eye."},{"key":"B44","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.ejpn.2020.10.007","article-title":"E.U. paediatric MOG consortium consensus: part 4 \u2013 outcome of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders","volume":"29","author":"Bruijstens","year":"2020","journal-title":"Eur J Paediatr Neurol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"e055392","DOI":"10.1136\/bmjopen-2021-055392","article-title":"Predictors of relapse in MOG antibody associated disease: a cohort study","volume":"11","author":"Huda","year":"2021","journal-title":"BMJ Open."},{"key":"B46","doi-asserted-by":"publisher","first-page":"65","DOI":"10.3988\/jcn.2024.0276","article-title":"Phenotype of relapsing myelin oligodendrocyte glycoprotein antibody-associated disease in Children","volume":"21","author":"Han","year":"2025","journal-title":"J Clin Neurol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1136\/jnnp-2022-330237","article-title":"Prognostic relevance of quantitative and longitudinal MOG antibody testing in patients with MOGAD: a multicentre retrospective study","volume":"94","author":"Matteo","year":"2023","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B48","doi-asserted-by":"publisher","first-page":"e111","DOI":"10.1212\/WNL.0000000000009758","article-title":"Steroid-sparing maintenance immunotherapy for MOG-IgG associated disorder","volume":"95","author":"Chen","year":"2020","journal-title":"Neurology."},{"key":"B49","doi-asserted-by":"publisher","first-page":"e705","DOI":"10.1212\/NXI.0000000000000705","article-title":"Long-term efficacy of mycophenolate mofetil in myelin oligodendrocyte glycoprotein antibody-associated disorders","volume":"7","author":"Li","year":"2020","journal-title":"Neurology."},{"key":"B50","doi-asserted-by":"publisher","first-page":"3565","DOI":"10.1007\/s00415-020-10026-y","article-title":"Treatment of MOG antibody associated disorders: results of an international survey","volume":"267","author":"Whittam","year":"2020","journal-title":"J Neurol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"104571","DOI":"10.1016\/j.msard.2023.104571","article-title":"Meta-analysis of the effectiveness of relapse prevention therapy for myelin-oligodendrocyte glycoprotein antibody-associated disease","volume":"72","author":"Chang","year":"2023","journal-title":"Mult Scler Relat Disord."},{"key":"B52","doi-asserted-by":"publisher","first-page":"192","DOI":"10.3390\/biomedicines10010192","article-title":"Neuroprotective effects of novel treatments on acute optic neuritis\u2013a meta-analysis","volume":"10","author":"Tsai","year":"2022","journal-title":"Biomedicines"},{"key":"B53","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1186\/s13287-021-02645-7","article-title":"Emerging concepts in the treatment of optic neuritis: mesenchymal stem cell-derived extracellular vesicles","volume":"12","author":"Aneesh","year":"2021","journal-title":"Stem Cell Res Ther."},{"key":"B54","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/S1474-4422(19)30137-1","article-title":"Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial","volume":"18","author":"Cadavid","year":"2019","journal-title":"Lancet Neurol."},{"key":"B55","author":"Biogen","year":"2020","journal-title":"Biogen Reports Q3 2020 Results"},{"key":"B56","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.stem.2020.03.017","article-title":"Problems and pitfalls of identifying remyelination in multiple sclerosis","volume":"26","author":"Neumann","year":"2020","journal-title":"Cell Stem Cell."},{"key":"B57","doi-asserted-by":"publisher","first-page":"232","DOI":"10.4103\/1673-5374.128213","article-title":"Gene therapy and the regeneration of retinal ganglion cell axons","volume":"9","author":"Harvey","year":"2014","journal-title":"Neural Regen Res."},{"key":"B58","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s13024-023-00655-y","article-title":"Retinal ganglion cell repopulation for vision restoration in optic neuropathy: a roadmap from the RReSTORe consortium","volume":"18","author":"Soucy","year":"2023","journal-title":"Mol neurodegener"},{"key":"B59","first-page":"243","article-title":"Chapter 15 - Gene and cell-based therapies for retinal and optic nerve disease","volume-title":"Handbook of Clinical Neurology.","author":"Esposito","year":"2024"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2025.1605075\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T03:22:59Z","timestamp":1750216979000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2025.1605075\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,18]]},"references-count":59,"alternative-id":["10.3389\/fneur.2025.1605075"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2025.1605075","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,18]]},"article-number":"1605075"}}